SavedAdd your journal

Journals / Toplum ve Hekim / 2012 / Cilt: 27 - Sayı: 1

Introducing pentavalent vaccine in India: How public interest litigation forced a Re-evaluation of the evidence

Hindistan'da pentavalent aşı uygulaması: Kamu çıkarı davası kanıtların yeniden değerlendirilmesini nasıl zorunlu kıldı

Jacob PULIYEL
Pages
75–80
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article describes how in India, given this background, a public interest petition was filed the Delhi High Court that forced the National Technical Advisory Group on Immunization and the Government of India to re-evaluate the evidence for its decisions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Haemophilus influenzae type b (Hib) disease is rare in Asia.
📊
Key Findings & Data:Right up to 2007 the WHO recommended that countries must consider Hib burden before introducing the Hib vaccine.
💡
Conclusion & Impact:This article describes how in India, given this background, a public interest petition was filed the Delhi High Court that forced the National Technical Advisory Group on Immunization and the Government of India to re-evaluate the evidence for its decisions.
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

Haemophilus influenzae type b (Hib) disease is rare in Asia. Right up to 2007 the WHO recommended that countries must consider Hib burden before introducing the Hib vaccine. Inexplicably, after 'probe studies' in Indonesia and Bangladesh found that Hib vaccine did not reduce the incidence of pneumonia or meningitis significantly in these countries, the WHO modified its position paper to recommend inclusion of Hib vaccine in all routine immunization programmes. The WHO has been advocating replacement of the Diphtheria Pertussis Tetanus (DPT) vaccine with a Pentavalent vaccine including Hepatitis B and Hib vaccines. The Pentavalent vaccine increased to cost of DPT thirty fold. There have been reports of death in Sri Lanka, Pakistan and Bangladesh, following vaccination with Pentavalent vaccine. This article describes how in India, given this background, a public interest petition was filed the Delhi High Court that forced the National Technical Advisory Group on Immunization and the Government of India to re-evaluate the evidence for its decisions.

Özet

B tipi Haemophilus influenzae (Hib) hastalığı Asya'da nadir görülmektedir. DSÖ 2007 yılına kadar ülkelere, Hib aşısına geçmeden önce Hib yükünü değerlendirmelerini önermekteydi. Ancak, anlaşılmaz biçimde, Endonezya ve Bangladeş'te yapılan 'yoklama araştırmaları' Hib aşısının bu ülkelerdeki pnömoni veya menenjit vakalarını önemli ölçüde azaltmadığını gösterdikten sonra DSÖ konumunu değiştirerek Hib aşılamasının tüm rutin bağışıklama programlarında yer almasını tavsiye etmiştir. DSÖ, Difteri Boğmaca Tetanoz (DBT) aşısının, Hepatit B ve Hib aşıları dahil olmak üzere Pentavalent aşısıyla değiştirilmesini savunmaktadır. Pentavalent aşısı DBT'nin otuz katına mal olmaktadır. Sri Lanka, Pakistan ve Bangladeş gibi ülkelerde Pentavalent aşısı sonrasında ölüm olaylarının meydana geldiği bildirilmektedir. Makale, yukarıda özetlenen geri plan üzerine, Hindistan Hükümeti Bağışıklama Ulusal Teknik Danışma Grubu'nun verilen kararlara temel oluşturan kanıtların yeniden değerlendirilmesi için Delhi Yüksek Mahkemesi'ne yaptığı kamu çıkarı başvurusu sürecini anlatmaktadır.

🔖

Cite This Article

PULIYEL, J. (2012). Introducing pentavalent vaccine in India: How public interest litigation forced a Re-evaluation of the evidence. Toplum ve Hekim, Cilt: 27 - Sayı: 1, 75–80. https://ajindex.com/articles/367797

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Tastan Y, Alikasifoglu M, liter O, et al. (2000) Natural immunity to Haemophilus influenzae type b among healthy children in Istanbul, Turkey. Indian Pediatr 2000;37:414-7.
  2. Michaels RH, No.rden CW. (1997) Pharyngeal colonization with H influenzae type b: A longitudinal study of families with a child with meningitis or epiglottitis due to H influenzae type b. J Infect Dis 1977;136:222-8.
  3. Acharya D, Bhave S, Joshi V, Bavdekar A, Pandit A. (1997)Haemophilus influenzae type B vaccine in India: Need and timing, immunogenecity and tolerance. Indian Pediatr 1997;34:9-15.
  4. Kumar A, Dutta AK, Saili A, et al. (1997) Immunogenecity and tolerance of H influenzae type b, tetanus toxoid conjugate vaccine given concurrently or in combination. Indian j Pediatr 1997;64:839-47.
  5. Phadke MA, Kulkarni MV, Sovani VB, (1997) et al. Immunogenicity study of Haemophilus influenzae type b conjugate vaccine in Indian infants. Indian Pediatr 1997;34:779-83.
  6. Acharya D, Desai A, Nanavaty N, et al. (1995) Evaluation of immunogenicity and tolerance of single dose Haemophilus influenzae type b (PRP-T) vaccine. Indian Pediatr 1995;32:1077-82
  7. Acharya D, Bhave S, joshi V, Bavdekar A, Pandit A. (1997) Haemophilus influenzae type B vaccine in India: Need and timing, immunogenecity and tolerance. Indian Pediatr 1997;34:9-15.
  8. Dajani AS, Asmar B, (1979) Thirumoorthi MC. Systemic Haemophilus influenzae disease: an overview. J Pediatr 1979;94:355-64.
  9. Levine OS, Schwartz B, Pierce N, Kane M. (1998) Development, evaluation and implementation of haemophilus influenzae type b vaccines for young children in developing countries: current status and priority actions. Pediatr Infect Dis J; 17(5):95-113.
  10. Lau YL. (1999) Haemophilus influenzae type b diseases in Asia. Bull World Health Organ. 1999;77(11):867-8.
  11. Bradshaw MW, Schneerson R, Parke JC,et al. (1971) Bacterial antigens cross reactive with capsular polysaccharide of Haemophilus influenzae type b. Lancet 1971;1:1095-8.
  12. Robbins JB, Schneerson R, Argaman M, Handzel ZT. (1973) Haemophilus influenzae type b: Disease and immunity in humans. Ann Internal Med;78:259-69.
  13. Puliyel JM, Agarwal KS, Abed Abass F. (2001) Natural immunity to Haemophilus influenza b in infancy in Indian children. Vaccine. 2001 Sep 14;19(32):4592-4).
  14. Lone Z, Puliyel JM. (2010) Introducing pentavalent vaccine in the EPI in India: a counsel for caution. Indian J Med Res. 2010 Jul;132:1 -3. Minz S, Balraj V, Lalitha MK, Murali N, Cherian T, Manoharan G, Kadirvan S, Joseph A, Steinhoff MC.